Goldman Sachs Adjusts Price Target on Danaher to $225 From $220, Maintains Neutral Rating
Barclays Remains a Buy on Eli Lilly & Co (LLY)
Eli Lilly and Co Analyst Ratings
Analysts Offer Insights on Healthcare Companies: R1 RCM (RCM), Legend Biotech (LEGN) and Intuitive Surgical (ISRG)
Goldman Sachs Adjusts Price Target on Eli Lilly & Co. to $793 From $785, Maintains Neutral Rating
AbbVie Analyst Ratings
Intuitive Surgical Analyst Ratings
Danaher Analyst Ratings
Boston Scientific Analyst Ratings
Evercore ISI Cuts Price Target on Danaher to $260 From $266, Maintains Outperform Rating
Evercore ISI Adjusts Price Target on Boston Scientific to $81 From $78, Maintains Outperform Rating
Evercore ISI Adjusts Price Target on Intuitive Surgical to $425 From $385, Maintains In-line Rating
Maintaining Hold on Neurocrine Biosciences Amid Efficacy Concerns and Competitive Pressures
Buy Rating Affirmed for AbbVie on Strong Aesthetics Market Position and Positive Sales Outlook
Eli Lilly and Co Analyst Ratings
Deutsche Numis Remains a Hold on Boston Scientific (BSX)
Amgen Analyst Ratings
Eli Lilly and Co Analyst Ratings
Truist Securities Reiterates Buy on Eli Lilly and Co, Raises Price Target to $1000
Eli Lilly and Co Analyst Ratings